Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae
AUTOR(ES)
Blondeau, Joseph M.
FONTE
American Society for Microbiology
RESUMO
The mutant prevention concentration (MPC) represents a threshold above which the selective proliferation of resistant mutants is expected to occur only rarely. A provisional MPC (MPCpr) was defined and measured for five fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Based on their potential for restricting the selection of resistant mutants, the five fluoroquinolones, in descending order, were found to be moxifloxacin > trovafloxacin > gatifloxacin > grepafloxacin > levofloxacin. For several compounds, 90% of about 90 clinical isolates that lacked a known resistance mutation had a value of MPCpr that was close to or below the serum levels that could be attained with a dosing regimen recommended by the manufacturers. Since MPCpr overestimates MPC, these data identify moxifloxacin and gatifloxacin as good candidates for determining whether MPCpr can be used as a guide for choosing and eventually administering fluoroquinolones to significantly reduce the development of resistance.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=90309Documentos Relacionados
- Mutant Prevention Concentration of Gemifloxacin for Clinical Isolates of Streptococcus pneumoniae
- Mutant Prevention Concentrations for Single-Step Fluoroquinolone-Resistant Mutants of Wild-Type, Efflux-Positive, or ParC or GyrA Mutation-Containing Streptococcus pneumoniae Isolates
- Accumulation of 10 Fluoroquinolones by Wild-Type or Efflux Mutant Streptococcus pneumoniae
- Propensity of Fluoroquinolones with Different Moieties at Position 8 to Cause Resistance Development in Clinical Isolates of Streptococcus pneumoniae
- Ribosomal Mutations in Streptococcus pneumoniae Clinical Isolates
